Skip to main content
CIHR funding announced for CCTG PR25

CIHR funding announced for CCTG PR25

The CIHR has announced funding, $1,828,350 over 6 years, for the CCTG PR25 trial, a metastatic prostate cancer personalized medicine study investigating the addition platinum-based chemotherapy to standard of care chemotherapy to evaluate markers believed to predict benefit.

More >>
 
 CCTG NE2 trial has been awarded $260,101 in the Spring CIHR grants announcement

CCTG NE2 trial successfully funded by CIHR

​The CCTG NE2 trial has been awarded $260,101 in the Spring CIHR grants announcement to support Canadian participation in the STOPNET clinical trial international trial, a Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours.

More >>
 
CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial

CIHR has announces funding for the TACtful cell therapy trial

CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial investigating a novel cell therapy using the immune system to treat people with relapsed and refractory multiple myeloma.

More >>
 
Founding Director of the Canadian Cancer Trials Group, appointed to the Order of Canada

Founding Director of the Canadian Cancer Trials Group, appointed to the Order of Canada

Dr. Joseph Pater has been recognized for a lifetime of work in cancer research with his appointment as an Officer of the Order of Canada. The honor acknowledges the impact of his dedication to clinical research which has improved the lives of Canadians with cancer.

More >>
 

Planned trials

AL6

MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML

ALC7

Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials

ALC8

Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)

ALC9

Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)

BR37

Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy

CE9

Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)

CO32

Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial

ES3

NEEDS: NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed)

HN13

Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)

MAC29

OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

MD1

CALMS: Combination Therapy with Luspatercept in Lower Risk MDS

ME17

Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade Compared to Immune Checkpoint Blockade Alone in Patients with Advanced Melanoma

NE2

STOPNET - Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Med-Gut Tumours

PR25

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes

SC29

Stereotactic Body Radiotherapy to Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases

SC30

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT

VU2

STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study

Recently activated

GA4

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma

More >>

HD12

PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)

More >>

I244

Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma

More >>

ME13L

A Biomarker Sub-study of the CCTG ME.13 Duration of Anti PD-1 Therapy in Metastatic Melanoma STOP-GAP Trial

More >>

MY13

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma

More >>

SC28

The SEAMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS

More >>
David McMullen CCTG patient rep

CCTG Patient Representative David McMullen honoured with 2023 CCRA award

The Canadian Cancer Research Alliance (CCRA) announced the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.

More >>
 
Funding announced for CAR-T ethics study

Funding announced for CAR-T ethics study

A new CCTG national study has received funding from the Social Sciences and Humanities Research Council and Genome Canada to explore the ethical questions raised with emerging cancer technologies like CAR-T cell therapy.

More >>
 
Fighting a rare battle

Fighting a rare battle

Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.

More >>
 
Integrating Patient Centred Research in the Canadian Cancer Trials Group

Integrating Patient Centred Research in the Canadian Cancer Trials Group

A paper has recently been published in Current Oncology outlining the incorporation of patient engagement in the development of clinical trial at the Canadian Cancer Trials Group (CCTG).

More >>
 

Publications

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

N Engl J Med 388: 2159 - 2170, 2023
Eskander RN;Sill MW;Beffa L;Moore RG;Hope JM;Musa FB;Mannel R;Shahin MS;Cantuaria GH;Girda E;Mathews C;Kavecansky J;Leath CA;Gien LT;Hinchcliff EM;Lele SB;Landrum LM;Backes F;O'Cearbhaill RE;Al Baghdadi T;Hill EK;Thaker PH;John VS;Welch S;Fader AN;Powell MA;Aghajanian C;

More >>

Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial (ONLINE)

International Journal of Radiation Oncology*Biology*Physics , 2023
Petersen PM;Cook AD;Sydes MR;Clarke N;Cross W;Kynaston H;Logue J;Neville P;Payne H;Parmar MKB;Parulekar W;Persad R;Saad F;Stirling A;Parker CC;Catton C;

More >>

Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial (ONLINE)

The Oncol , 2023
Gupta A;Hay AE;Crump M;Djurfeldt MS;Zhu L;Cheung MC;Shepherd LE;Chen BE;Booth CM;

More >>

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

N Engl J Med 388: 1645 - 1656, 2023
Partridge AH;Niman SM;Ruggeri M;Peccatori FA;Azim HA;Colleoni M;Saura C;Shimizu C;Sætersdal AB;Kroep JR;Mailliez A;Warner E;Borges VF;Amant F;Gombos A;Kataoka A;Rousset-Jablonski C;Borstnar S;Takei J;Lee JE;Walshe JM;Ruíz-Borrego M;Moore HCF;Saunders C;Bjelic-Radisic V;Susnjar S;Cardoso F;Smith KL;Ferreiro T;Ribi K;Ruddy K;Kammler R;El-Abed S;Viale G;Piccart M;Korde LA;Goldhirsch A;Gelber RD;Pagani O;

More >>

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

Cancers 15: 1823, 2023
Karamouza E;Glasspool RM;Kelly C;Lewsley LA;Carty K;Kristensen GB;Ethier JL;Kagimura T;Yanaihara N;Cecere SC;You B;Boere IA;Pujade-Lauraine E;Ray-Coquard I;Proust-Lima C;Paoletti X;

More >>

Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6

Supportive Care in Cancer 31: 256, 2023
Mian H;Ringash J;Meyer R;Hay AE;Shepherd L;Djurfeldt M;Winter JN;Sussman J;Pater J;Chen BE;Prica A;

More >>